PFE logo Pfizer +
Pfizer
+

Pfizer (PFE) Business News

Track Pfizer in real time with a live news feed covering Pfizer stock news, official press releases, company announcements, and an archive of historical Pfizer news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff

24/7 Wall Street

11:48 AM | Tuesday | Oct 13, 2026

news photo
Loading...

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) stock is at $249.55, down 5% early in the session. The company raised its full-year outlook in the same release that showed its reported profit falling under one-time charges.

Read full article redirect
11:48 AM | Tuesday | Oct 13, 2026

Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff

24/7 Wall Street

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) stock is at $249.55, down 5% early in the session. The company raised its full-year outlook in the same release that showed its reported profit falling under one-time charges.

Read full article arrow
News Thumbnail
11:21 AM | Tuesday | Oct 13, 2026

FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban

Business Insider

The Federal Trade Commission said Martin Shkreli is still trading pharmaceutical stocks. The FTC said the "Pharma Bro" continues to do this despite a lifetime ban.

Read full article arrow
News Thumbnail
9:41 AM | Tuesday | Oct 13, 2026

A $750,000 Roth IRA Portfolio Loaded With These Dividend Stocks Pays $47,800 a Year and the IRS Gets None of It

247 Wallst

Six high-yield dividend stocks can quietly hand the IRS thousands of dollars every single year, but where you hold them changes everything. The bracket you sit in determines exactly how much you keep or surrender.

Read full article arrow
News Thumbnail
9:26 AM | Tuesday | Oct 13, 2026

Pfizer: The Earnings Test That Matters

Seeking Alpha

New and acquired products generated $3.2 billion in Q2, growing 18% YoY and approaching a $13 billion annualized run-rate. Pfizer has removed $7.2 billion from its cost base while beating EPS estimates in each of its last 10 quarters. COVID revenue is expected to fall to $4 billion in 2026, substantially reducing a major source of Pfizer's post-pandemic earnings pressure.

Read full article arrow
News Thumbnail
9:15 AM | Tuesday | Oct 13, 2026

These 6 Dividend Stocks Look Like Income Bargains. Their Payout Ratios Say Otherwise

24/7 Wall Street

Six stocks are flashing high yields that look like income bargains, but a closer look at their payout ratios tells a very different story about which ones can actually keep the checks coming.

Read full article arrow
News Thumbnail
7:00 AM | Tuesday | Oct 13, 2026

Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules

Business Wire

PARIS--(BUSINESS WIRE)-- #Biotech--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has entered into a research collaboration and license agreement with Pfizer Inc. to discover and develop Sec61 inhibitors. The collaboration aims to accelerate the discovery and advancement of novel small-molecule therapeutics leveraging Enodia's proprietary platform. Enodia's proprietary platform enables se.

Read full article arrow
News Thumbnail
12:00 PM | Monday | Oct 12, 2026

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool

Johnson & Johnson's fiscal 2025 sales rose about 6% to $94.2 billion, and its net income includes a roughly $7 billion reversal of its talc reserve. Pfizer says it expects a significant reduction in revenue from patent and regulatory exclusivity expiries from 2026 through 2030.

Read full article arrow
News Thumbnail
10:56 AM | Monday | Oct 12, 2026

Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock?

Zacks Investment Research

PFE moves above its 50-day SMA as newer drugs, oncology and obesity treatments fuel growth prospects, but declining COVID sales and patent expirations pose challenges.

Read full article arrow
News Thumbnail
9:15 AM | Monday | Oct 12, 2026

4 Blue Chip Giants That May Have to Cut Their Dividends

24/7 Wall Street

Four household names are paying dividend yields above 5%, but their earnings, cash flow, and balance sheets tell a different story than their press releases. Before you count on those checks arriving, there are some serious warning signs worth understanding.

Read full article arrow
News Thumbnail
10:35 AM | Sunday | Oct 11, 2026

Buy 9 S&P500 IDEAL "Safer" October Dividend Dogs

Seeking Alpha

I spotlight nine 'safer' S&P 500 Dogs, including VICI, KHC, and PFE, as prime dividend opportunities with strong free cash flow coverage. Analyst projections indicate top-ten S&P 500 Dogs could deliver 17.5%โ€“33.2% net gains by October 2027, with a 37.1% average net gain across the group.
Seven of the top ten 'safer' Dogs already meet the fair price standard, with only modest corrections needed for the remainder to align with ideal yield metrics.

Read full article arrow
News Thumbnail